According to filings with the U.S. Securities and Exchange Commission, Remedy Plan is raising $19,579,386.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Gregory Crimmins played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Remedy Plan
Our plan is to stop the spread of cancer without stopping your life. Cancer containment therapy is a new approach that aims to disrupt cancer growth without toxic side effects. Remedy Plan is developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis. Remedy Plan is positioned to disrupt and define the emerging field of cancer stem cell therapeutics. Our novel drug screening platform measures the most dangerous properties of cancer stem cells, allowing us to identify and develop drugs that disrupt proliferation and inhibit formation of new tumors. Our approach aims to disrupt metastasis and tumor growth by inhibiting the properties of cancer stem cells that allow them to spread and resist chemotherapy. Focusing on properties not found in healthy adult tissue ensures cancer stem cells are the only targets, making our approach both effective and non-toxic. Remedy Plan is a team of scientists and biotech entrepreneurs dedicated to tackling the biggest health problem of our time.

To learn more about Remedy Plan, visit http://remedyplan.com/

Contact:
Gregory Crimmins, Chief Executive Officer
240-459-3985
https://www.linkedin.com/in/gregory-crimmins-8662a518/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.